Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial)

Anticancer Research

Volumn 26, Issue 5 B, 2006, Pages 3877-3883

  Duffour, Jacqueline ^a   Bouché, Olivier ^b   Rougier, Philippe ^c   Milan, Chantal ^d   Bedenne, Laurent ^e   Seitz, Jean François ^f   Buecher, Bruno ^g   Legoux, Jean Louis ^h   Ducreux, Michel ^c   Vetter, Denis ⁱ   Raoul, Jean Luc ^j   François, Eric ^k   Ychou, Marc ^a  

^a CENTRE VAL D AURELLE   (France)

^b SERVICE DE DERMATOLOGIE   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d FFCD Dijon ^*  (France)

^e HÔPITAL DU BOCAGE   (France)

^f INSTITUT PAOLI CALMETTES   (France)

^g HÔTEL DIEU   (France)

^h CHU Pessac   (France)

ⁱ HÔPITAL CIVIL   (France)

^j CENTRE EUGÈNE MARQUIS   (France)

^k CENTRE ANTOINE LACASSAGNE   (France)

more..

Author keywords

5 fluorouracil; Cisplatin; Gastrointestinal cancer; Metastases

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID;

ADULT; ALOPECIA; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS CARCINOMA; FEMALE; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL ANALYSIS;

EID: 33750831270     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. De Besi P, Sileni VC, Salvagno L, Tremolada C, Cartei G, Fosser V, Paccagnella A, Peracchia A and Fiorentino M: Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer. Cancer Treat Rep 70: 909-910, 1986.
2. Stahl M, Wilke H, Meyer HJ, Preusser P, Berns T, Fink U, Achterrath W, Knipp H, Harstrick A, Berger M et al: 5-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus. Eur J Cancer 30A: 325-328, 1994.
3. Ilson DH, Sirott M, Saltz L, Heelan R, Huang Y, Keresztes R and Kelsen DP: A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. Cancer 75: 2197-2202, 1995.
4. Etienne MC, Bernard S, Fischel JL, Formento P, Gioanni J, Santini J, Demard F, Schneider M and Milano G: Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines. Br J Cancer 63: 372-377, 1991.
5. Kim NK, Park YS, Heo DS, Suh C, Kirn SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ et al: A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71: 3813-3818, 1993.
6. Lacave AJ, Baron FJ, Anton LM, Estrada E, De Sande LM, Palacio I, Esteban E, Gracia JM, Buesa JM, Fernandez OA et al: Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol 2: 751-754, 1991.
7. Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, Bognel C, Lasser P, Ychou M, Elias D et al: Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 30A: 1263-1269, 1994.
8. Ohtsu A, Shimada Y, Yoshida S, Saito H, Seki S, Morise K and Kurihara M: Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). Eur J Cancer 30A: 2091-2093, 1994.
9. Rougier P, Zarba JJ, Ducreux M, Basile M, Pignon JP, Mahjoubi M, Benahmed M, Droz JP, Cvitkovic E and Armand JP: Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann Oncol 4: 333-336, 1993.
10. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B and Wils JA: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18: 2648-2657, 2000.
11. Ducreux M, Rougier P, Pignon JP, Douillard JY, Seitz JF, Bugat R, Bosset JF, Merouche Y, Raoul JL, Ychou M, Adenis A, Berthault-Cvitkovic F and Luboinski M: A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 13: 1185-1191, 2002.
12. Machover D, Goldschmidt E, Chollet P, Metzger G, Zittoun J, Marquet J, Vandenbulcke JM, Misset JL, Schwarzenberg L, Fourtillan JB and et al: Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4: 685-696, 1986.
13. Poon MA, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, Levitt R, Kardinal CG and Mailliard JA: Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9: 1967-1972, 1991.
14. Dreyfuss AI, Clark JR, Wright JE, Norris CM Jr, Busse PM, Lucarini JW, Fallon BG, Casey D, Andersen JW, Klein R et al: Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann Intern Med 112: 167-172, 1990.
15. Loeffler TM, Lindemann J, Luckhaupt H, Rose KG and Hausamen TU: Chemotherapy of advanced and relapsed squamous cell cancer of the head and neck with split-dose cisplatinum (DDP), 5-fluorouracil (Fura) and leucovorin (CF). Adv Exp Med Biol 244: 267-273, 1988.
16. Ychou M, Astre C, Rouanet P, Fahre JM, Saint-Aubert B, Domergue J, Ribard D, Ciurana AJ, Janbon C and Pujol H: A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer. Eur J Cancer 32A: 1933-1937, 1996.
17. Andre T, Lotz JP, Bouleuc C, Azzouzi K, Houry S, Hannoun L, See J, Esteso A, Avenin D and Izrael V: Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma. Ann Oncol 7: 173-178, 1996.
18. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L and Sahmoud T: Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33: 1216-1220, 1997.
19. Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsene D, Paitel JF, Guerin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L and Milan C: Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study - FFCD 9803. J Clin Oncol 22: 4319-4328, 2004.
20. Philip PA, Zalupski MM, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun LK, Adsay V, Weaver D and Shields AF: Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 92: 569-577, 2001.
21. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E and Lopez M: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94: 902-910, 2002.